- Home
- BCTX vs SDOT Comparison
BCTX vs SDOT Comparison
Compare BCTX & SDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- SDOT
- Stock Information
- Founded
- BCTX 2014
- SDOT 2014
- Country
- BCTX Canada
- SDOT United States
- Employees
- BCTX N/A
- SDOT N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- SDOT Restaurants
- Sector
- BCTX Health Care
- SDOT Consumer Discretionary
- Exchange
- BCTX Nasdaq
- SDOT Nasdaq
- Market Cap
- BCTX 16.1M
- SDOT N/A
- IPO Year
- BCTX N/A
- SDOT 2020
- Fundamental
- Price
- BCTX $3.18
- SDOT $1.31
- Analyst Decision
- BCTX Strong Buy
- SDOT
- Analyst Count
- BCTX 1
- SDOT 0
- Target Price
- BCTX $32.00
- SDOT N/A
- AVG Volume (30 Days)
- BCTX 3.7M
- SDOT 30.1K
- Earning Date
- BCTX 06-13-2025
- SDOT 05-19-2025
- Dividend Yield
- BCTX N/A
- SDOT N/A
- EPS Growth
- BCTX N/A
- SDOT N/A
- EPS
- BCTX N/A
- SDOT 0.85
- Revenue
- BCTX N/A
- SDOT $700,937,000.00
- Revenue This Year
- BCTX N/A
- SDOT $12.76
- Revenue Next Year
- BCTX N/A
- SDOT $5.54
- P/E Ratio
- BCTX N/A
- SDOT $1.53
- Revenue Growth
- BCTX N/A
- SDOT N/A
- 52 Week Low
- BCTX $0.35
- SDOT $1.33
- 52 Week High
- BCTX $9.82
- SDOT $7.00
- Technical
- Relative Strength Index (RSI)
- BCTX 37.13
- SDOT 22.03
- Support Level
- BCTX $4.04
- SDOT $1.51
- Resistance Level
- BCTX $9.82
- SDOT $1.48
- Average True Range (ATR)
- BCTX 0.75
- SDOT 0.13
- MACD
- BCTX -0.22
- SDOT -0.00
- Stochastic Oscillator
- BCTX 1.34
- SDOT 7.36
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.